Tharimmune Beheer

Beheer criteriumcontroles 4/4

De CEO Tharimmune is Randy Milby, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 742.42K, bestaande uit 50.5% salaris en 49.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.87% van de aandelen van het bedrijf, ter waarde $ 33.76K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 3.3 jaar.

Belangrijke informatie

Randy Milby

Algemeen directeur

US$742.4k

Totale compensatie

Percentage CEO-salaris	50.5%
Dienstverband CEO	7.8yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Analyse CEO-vergoeding

Hoe is Randy Milby's beloning veranderd ten opzichte van Tharimmune's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$742k	US$375k	-US$9m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$3m	US$472k	-US$8m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$3m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$973k	n/a	-US$2m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$194k	n/a	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 742.42K ) Randy } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Randy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Randy Milby (70 yo)

7.8yrs

Tenure

US$742,415

Compensatie

Mr. Randy D. Milby, MBA is the Chairman and Chief Executive Officer of Tharimmune, Inc. (formerly known as Hillstream BioPharma, Inc.) since 2017. He is President at Tharimmune, Inc. (formerly known as Hil...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Randy Milby	President	7.8yrs	US$742.42k	0.87% $ 33.8k
Sireesh Appajosyula	COO & Director	1.3yrs	US$602.16k	0.90% $ 34.8k
Thomas Hess	Chief Financial Officer	3.4yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van THAR wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Randy Milby	President	7.8yrs	US$742.42k	0.87% $ 33.8k
Sireesh Appajosyula	COO & Director	3.3yrs	US$602.16k	0.90% $ 34.8k
Leonard Mazur	Independent Director	3.3yrs	US$34.43k	0.022% $ 861.4
Vaughn Smider	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kelly Anderson	Independent Director	1.5yrs	US$46.17k	0% $ 0
Lynne Bui	Independent Director	3.3yrs	US$41.57k	0% $ 0
John Lambert	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Jones	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Andreas Kremer	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Alan Bonder	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van THAR wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Tharimmune Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Tharimmune, Inc. Appoints David Jones to Its Scientific Advisory Board

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

No independent directors

Recent updates

Tharimmune, Inc. Presents Positive Clinical Data at AASLD Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune, Inc. (NasdaqCM:THAR) entered into a nonbinding, exclusive letter of intent to acquire Intract Pharma Ltd.

New major risk - Financial position

Tharimmune, Inc. Appoints David Jones to Its Scientific Advisory Board

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd